UK Cell Lysis And Disruption Market Size & Outlook
UK cell lysis and disruption market, 2018-2028 (US$M)
Related Markets
UK cell lysis and disruption market highlights
- The UK cell lysis and disruption market generated a revenue of USD 309.3 million in 2020 and is expected to reach USD 686.3 million by 2028.
- The UK market is expected to grow at a CAGR of 10.5% from 2021 to 2028.
- In terms of segment, reagent-based was the largest revenue generating technique in 2020.
- Reagent-based is the most lucrative technique segment registering the fastest growth during the forecast period.
Cell lysis and disruption market data book summary
| Market revenue in 2020 | USD 309.3 million |
| Market revenue in 2028 | USD 686.3 million |
| Growth rate | 10.5% (CAGR from 2020 to 2028) |
| Largest segment | Reagent-based |
| Fastest growing segment | Reagent-based |
| Historical data | 2018 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2028 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Reagent-based, Physical Disruption |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Rad Laboratories Inc, Roche Holding AG ADR, Qiagen NV, Danaher Corp, Miltenyi Biotec, IDEX Corp, BD, Claremont BioSolutions, Parr Instrument Company, Covaris, Cell Signaling Technology, Qsonica |
Other key industry trends
- In terms of revenue, UK accounted for 7.6% of the global cell lysis and disruption market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2028.
- In Europe, Germany cell lysis and disruption market is projected to lead the regional market in terms of revenue in 2028.
- UK is the fastest growing regional market in Europe and is projected to reach USD 686.3 million by 2028.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cell Lysis And Disruption Market Scope
Cell Lysis And Disruption Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK cell lysis and disruption market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell lysis and disruption market will help companies and investors design strategic landscapes.
Reagent-based was the largest segment with a revenue share of 61.75% in 2020. Horizon Databook has segmented the UK cell lysis and disruption market based on reagent-based, physical disruption covering the revenue growth of each sub-segment from 2018 to 2028.
The UK cell lysis & disruption market is characterized by several government and non-government organizations that encourage research in biotechnology and associated fields of sciences. For instance, the BioIndustry Association (BIA) a trade association for inventive life sciences in the UK promotes an environment that enables innovative life sciences firms
to start and grow sustainably and successfully. The association aims at securing UK’s position as a global hub and one of the best locations for commercialization and innovative research for biotechnology.
According to the 2018 annual Biosimilar Medicines Conference in London, the uptake of etanercept, infliximab, and rituximab biosimilars has increased in the UK. The biosimilar for infliximab, which was initially launched in the UK in 2015.
Reasons to subscribe to UK cell lysis and disruption market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK cell lysis and disruption market databook
-
Our clientele includes a mix of cell lysis and disruption market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK cell lysis and disruption market , including forecasts for subscribers. This country databook contains high-level insights into UK cell lysis and disruption market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Partial client list
UK cell lysis and disruption market size, by technique, 2018-2028 (US$M)
UK Cell Lysis And Disruption Market Outlook Share, 2020 & 2028 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
